Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
Abstract:
The present application relates to antibodies, such as monoclonal antibodies, and in particular CDR grafted, humanized versions thereof, for the treatment and diagnosis of pain and other neuroinflammatory conditions associated with the Receptor for Advanced Glycation End Products (RAGE).
Information query
Patent Agency Ranking
0/0